Press Releases

News Release - October 29, 2018
AMO Pharma Reports Positive Data from Investigator-Led TIDE Study of AMO-02 in Autism Spectrum Disorder


News Release - October 23, 2018
AMO Therapeutics Announces Presentation of Concordant Analysis of Results of Phase 2 Study of AMO-02 in treatment of myotonic dystrophy


News Release - June 13, 2018
AMO Pharma Receives FDA Orphan Drug Designation for AMO-04 in Treatment of Rett Syndrome


News Release - May 7, 2018
AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome


News Release - March 15, 2018
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1


News Release - October 18, 2017
AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting


News Release - September 25, 2017
AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study


News Release - July 20, 2017
AMO Pharma Enters into Development and License Agreement with Numedicus Limited for Rett Syndrome Program


News Release - May 30, 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy


News Release - March 14, 2017
AMO Pharma Enters into Collaboration Agreement with Ranedis Pharmaceuticals for Development of RND-001


News Release - February 28, 2017
AMO Pharma Joins with Leaders in Patient and Caregiver Advocacy to Commemorate Rare Disease Day


News Release - August 10, 2016
AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy


News Release - June 7, 2016
AMO Pharma Presents Pre-clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated with Fragile X Syndrome


News Release - Apr 18, 2016
Joseph Horrigan Joins AMO Pharma as Chief Medical Officer


News Release - Sept 30, 2015
AMO Pharma Ltd. Closes $25M Private Equity Financing with Woodford Patient Capital Trust plc


In the Media

Can a Pharma Drug Improve Autism Conditions? - November 1, 2018

https://www.biospace.com/article/can-a-pharma-drug-improve-autism-conditions-

 

Tideglusib Improves Myotonic Dystrophy Type 1 Neuromuscular Symptoms - October 31, 2018

https://www.neurologylive.com/clinical-focus/tideglusib-improves-patients-myotonic-dystrophy-type-1

 

AMO Pharma Reports Positive Results from AMO-02 Trial - October 30, 2018

https://www.drugdevelopment-technology.com/news/amo-pharma-reports-positive-results-from-tide-trial/

 

Positive Data for AMO-02 in Autism Spectrum Disorder - October 30, 2018

https://www.thepharmaletter.com/article/positive-data-for-amo-02-in-autism-spectrum-disorder

 

Orphan Drug Update: Phase 2 Study Shows Promise in Congenital and Childhood Onset Myotonic Dystrophy Type 1 - October 28, 2018

https://medicalresearch.com/pediatrics/orphan-drug-update-phase-2-study-shows-promise-in-congenital-and-childhood-onset-myotonic-dystrophy-type-1/45536

 

FDA Grants Orphan Drug Designation to New Treatment for Rett Syndrome - June 15, 2018

https://www.raredr.com/news/fda-grants-orphan-drug-designation-to-new-treatment-for-rett-syndrome

 

Phelan-McDermid Syndrome Treatment Commences Clinical Trial Recruitment - May 11, 2018

http://www.raredr.com/news/phelanmcdermid-syndrome-treatment-commences-clinical-trial-recruitment

 

AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome - May 8, 2018

http://www.checkorphan.org/news/amo-pharma-announces-initiation-of-clinical-trial-conducted-by-mount-sinai-to-study-amo-01-in-treatment-of-phelan-mcdermid-syndrome

 

AMO Pharma Advancing Ultra-Rare Program on Back of Phase IIb Data - April 10, 2018

http://www.bioworld.com/content/amo-pharma-advancing-ultra-rare-program-back-phase-iib-data/

 

Early Clinical Trials of AMO-02 Show Promise in Congenital and Childhood Myotonic Dystrophy Type 1 - March 23, 2018

https://medicalresearch.com/author-interviews/early-clinical-trials-of-amo-02-show-promise-in-congenital-and-childhood-myotonic-dystrophy-type-1/40741/

 

Companies pair up to take Rett Syndrome program into clinic - July 20, 2017

https://www.thepharmaletter.com/article/companies-pair-up-to-take-rett-syndrome-program-into-clinic/

 

News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact - July 20, 2017

http://www.fiercebiotech.com/biotech/news-note-trevena-cmo-exit-amo-deal-kala-ipo-alivecor-mayo-pact

 

FDA Gives Fast Track Status to Potential Therapy for Congenital Myotonic Dystrophy - June 1, 2017

https://musculardystrophynews.com/2017/06/01/amo-02-congenital-myotonic-dystrophy-treatment-gains-fda-fast-track/

 

AMO Pharma receives FDA Fast Track Status - May 30, 2017

http://european-biotechnology.com/up-to-date/latest-news/news/amo-pharma-receives-fda-fast-track-status.html

 

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - May 30, 2017

http://labiotech.eu/amo-pharma-amo-02-myotonic-dystrophy/

 

AMO Pharma Addresses Rare Childhood Disease - May 22, 2017

https://www.clinicalleader.com/doc/amo-pharma-addresses-rare-childhood-disease-0001

 

Ranedis and AMO Partner to Develop HDAC Inhibitor for Rare Genetic Diseases - March 14, 2017

http://www.genengnews.com/gen-news-highlights/ranedis-and-amo-partner-to-develop-hdac-inhibitor-for-rare-genetic-diseases/81254020

 

AMO Pharma and Ranedis target rare genetic diseases in RND-001 deal - March 14, 2017

https://www.thepharmaletter.com/article/amo-pharma-and-ranedis-target-rare-genetic-diseases-in-rnd-001-deal

 

Wayne-Based AMO Pharma Raises $25 Million - October 1, 2015

https://patch.com/pennsylvania/te/wayne-based-amo-pharma-raises-25-million

 

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma - October 1, 2015

http://labiotech.eu/neil-woodford-amo-pharma-25m/


Subscribe
Stay updated about AMO! Enter your information here to receive updates about AMO Pharma via email:



Unsubscribe
To unsubscribe from all AMO Pharma communications, please click here.